| Year |
Citation |
Score |
| 2023 |
Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL. Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells. Transplantation and Cellular Therapy. PMID 37211154 DOI: 10.1016/j.jtct.2023.05.011 |
0.302 |
|
| 2017 |
Cummins KD, Frey N, Nelson AM, Schmidt A, Luger S, Isaacs RE, Lacey SF, Hexner E, Melenhorst JJ, June CH, Porter DL, Gill SI. Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells Blood. 130: 1359-1359. DOI: 10.1182/Blood.V130.Suppl_1.1359.1359 |
0.307 |
|
| 2015 |
Mato A, Porter DL. A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood. 126: 478-85. PMID 26065655 DOI: 10.1182/blood-2015-03-585091 |
0.32 |
|
| 2015 |
June CH, Porter D, Grupp S, Levine BL. Abstract IA10: CARs for leukemia and beyond? Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-Ia10 |
0.313 |
|
| 2014 |
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, ... ... Porter DL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine. 371: 1507-17. PMID 25317870 DOI: 10.1056/Nejmoa1407222 |
0.326 |
|
| 2013 |
Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 1094-101. PMID 23635453 DOI: 10.1016/J.Bbmt.2013.04.021 |
0.312 |
|
| 2012 |
Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transplantation. 47: 940-5. PMID 22020023 DOI: 10.1038/bmt.2011.201 |
0.317 |
|
| 2011 |
Waller EK, Harris WA, Devine S, Porter DL, Mineishi S, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Gurgol C, Logan BR, Confer DL, et al. Larger Numbers of Donor Naïve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201 Blood. 118: 1004-1004. DOI: 10.1182/Blood.V118.21.1004.1004 |
0.301 |
|
| 2010 |
Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL. Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL). Blood. 116: 4574-4574. DOI: 10.1182/BLOOD.V116.21.4574.4574 |
0.301 |
|
| 2006 |
Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation Blood. 107: 1325-1331. PMID 16269610 DOI: 10.1182/Blood-2005-08-3373 |
0.306 |
|
| 2004 |
Goldstein SC, Luger SM, Stadtmauer E, Schuster S, Tsai D, Nasta S, Loren A, Perl A, Orloff G, Oliver J, Sachs R, Emerson S, Porter DL. Non-Myeloablative Conditioning with Allogeneic Progenitor Cell Transplantation for Relapsed Hodgkin’s Lymphoma: High Response Rate Despite Prior Chemoresistance. Blood. 104: 2258-2258. DOI: 10.1182/BLOOD.V104.11.2258.2258 |
0.303 |
|
| 2004 |
Porter D, Levine B, Bunin N, Stadtmauer E, Luger S, Goldstein S, Schuster S, Tsai D, Nasta S, Loren A, Perl A, Oliver J, Sohal A, Veloso L, Emerson S, et al. Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation. Blood. 104: 1640-1640. DOI: 10.1182/Blood.V104.11.1640.1640 |
0.307 |
|
| 2001 |
Bhatia V, Porter DL. Novel approaches to allogeneic stem cell therapy Expert Opinion On Biological Therapy. 1: 3-15. PMID 11727545 DOI: 10.1517/14712598.1.1.3 |
0.303 |
|
| Show low-probability matches. |